Simona Ferjan

Ljubljana, 1000, Slovenia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Semaglutide and Taste in Women With Obesity and Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Study.

Semaglutide and Taste in Women With Obesity and Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Study.

Journal: The Journal of clinical endocrinology and metabolism

Published: December 11, 2024

Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review.

Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review.

Journal: Frontiers in endocrinology

Published: November 14, 2024

The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study.

The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study.

Journal: Frontiers in endocrinology

Published: January 07, 2024

Prolactin in Polycystic Ovary Syndrome: Metabolic Effects and Therapeutic Prospects.

Prolactin in Polycystic Ovary Syndrome: Metabolic Effects and Therapeutic Prospects.

Journal: Life (Basel, Switzerland)

Published: September 19, 2023

Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity.

Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity.

Journal: Diabetes, obesity & metabolism

Published: September 14, 2022

Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study.

Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study.

Journal: Diabetes research and clinical practice

Published: May 28, 2021

Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial.

Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial.

Journal: Trials

Published: April 02, 2021

Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort.

Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort.

Journal: Endocrine connections

Published: November 19, 2019

An impaired glucagon-like peptide-1 response is associated with prediabetes in polycystic ovary syndrome with obesity.

An impaired glucagon-like peptide-1 response is associated with prediabetes in polycystic ovary syndrome with obesity.

Journal: The Journal of international medical research

Published: August 24, 2019

DPP4 INHIBITOR SITAGLIPTIN AS A POTENTIAL TREATMENT OPTION IN METFORMIN-INTOLERANT OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME: A PILOT RANDOMIZED STUDY.

DPP4 INHIBITOR SITAGLIPTIN AS A POTENTIAL TREATMENT OPTION IN METFORMIN-INTOLERANT OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME: A PILOT RANDOMIZED STUDY.

Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Published: November 18, 2017

Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study.

Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study.

Journal: Metabolic syndrome and related disorders

Published: October 25, 2017

Showing 1-11 of 11

Last Updated: 09/26/2026